A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

So a "generic" version of insulin would be something called a biosimilar. Unlike generics for chemical-based drugs (think antibiotics or birth-control pills) that can be interchangeable with ...

as the first rapid-acting insulin biosimilar to Novolog (insulin aspart). This new treatment option, aimed at enhancing ...

Semglee has been approved for over a year as a regular biosimilar to Lantus (insulin glargine), meaning that it could be used in place of Sanofi's drug, but only if specifically prescribed for a ...

Legislation introduced by Utah Senator Mike Lee would eliminate testing to show a biosimilar can be substituted ... Eli Lilly is slashing prices for its insulin products and capping a patient ...

The US Food and Drug Administration approved the first-ever rapid-acting insulin for reducing blood sugar levels. It calls the new drug “Merilog,” a biosimilar to the widely-used insulin ...

This will allow pharmacy level substitution and thereby provide convenient and affordable access to Semglee, a quality Biosimilar Insulin Glargine.” Biocon Biologics Managing Director Arun ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...